Meta-analysis of Human Papillomavirus Infection Concordance by Reiter, Paul L. et al.
Meta-analysis of human papillomavirus infection concordance
Paul L. Reiter1,2, William F. Pendergraft III3, and Noel T. Brewer1,2
1Gillings School of Global Public Health, University of North Carolina at Chapel Hill
2Lineberger Comprehensive Cancer Center
3Department of Medicine, University of California at San Francisco
Abstract
Background—Estimates of human papillomavirus (HPV) concordance among sexual partners are
important for various public health activities, from counseling individual patients to predicting the
impact of HPV vaccination.
Methods—We systematically searched PubMed and EMBASE for studies of HPV concordance
among heterosexual couples published through 2008 in English. Two coders independently
abstracted data using standardized forms. We integrated concordance data using random-effects
meta-analysis.
Results—Thirty studies (33 study populations) that met inclusion criteria reported concordance
data for 2,972 couples. Most studies were cross-sectional, cohort studies conducted in Europe or Asia
that used DNA hybridization to test for HPV, sometimes in conjunction with polymerase chain
reaction (PCR). Overall, 25.5% (95% CI: 17.2%-36.1%) of couples were infected with 1 or more of
the same HPV types. Among couples with both members HPV-positive, 63.2% (95% CI:
49.1%-75.3%) were infected with 1 or more of the same viral types. Positive concordance was higher
for female partners of men with HPV infections than for male partners of women with HPV infections.
Positive concordance was also higher for studies using PCR and for the few studies that recruited
men with HPV-related disease.
Conclusions—Sexual partners of HPV-infected individuals had high rates of HPV infection,
suggesting a need for increased attention to this group.
Impact—Our refined estimates of HPV concordance can inform clinical encounters and public
health planning. Future HPV concordance studies should use more rigorous research designs,
characterize their participants in greater detail, and study more meaningful populations.
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Introduction
Anogenital human papillomavirus (HPV) infection is a common sexually transmitted infection
(STI) that preferentially infects squamous epithelial cells (1,2). At least twenty million people
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in the U.S. are currently infected with HPV, and 5.5 million people become infected annually
(3). Although most HPV infections clear spontaneously (4–6), some nononcogenic HPV types
(mainly types 6 and 11) cause anogenital warts (7,8). Persistent infection with oncogenic HPV
types, if left untreated, can lead to cancers of the cervix, vagina, vulva, penis, anus, oropharynx,
and possibly skin and lung (9–12). Most cervical cancer deaths occur in the developing world
(13), primarily because of lack of access to screening and treatment. While the U.S. has much
lower rates of cervical cancer, it spends about $4 billion annually on treating and managing
cervical disease and anogenital warts (14) and an additional $418 million annually on other
HPV-related diseases (15).
A key contributor to the incidence of HPV-related disease is the high transmissibility of HPV,
estimated to be 40% (median value with range of 5%-100%) per unprotected sexual act (16).
Persistent HPV infection also increases the risk for disease and sexual partners acquiring the
virus. Among women, the median duration of infection is usually less than a year, but oncogenic
HPV infections last longer than nononcogenic HPV infections (4,6,17,18). Although fewer
data on infection duration have been reported for men, findings suggest that HPV infections
clear more quickly for men than for women, and men have similar duration of infection for
oncogenic and nononcogenic HPV types (5). While the extent to which sexual partners both
harbor anogenital HPV infection has important implications for public health, including
helping to understand the risks that partners of infected individuals face and increasing the
precision of HPV vaccine cost-effectiveness analyses, previous studies of HPV concordance
have yielded mixed findings. To address this question, we conducted a systematic review and
meta-analysis of the existing literature on HPV DNA concordance among heterosexual
couples.
Materials and Methods
Data Sources and Searches
Two investigators (PR and WP) independently searched PubMed and EMBASE databases for
studies published through December 2008 whose title, abstract, or keywords referred to HPV
infection or concordance among sexual partners. Search terms were ((HPV OR human
papillomavirus) OR (papillomavirus infection)) AND (transmission OR concordance). We
also manually searched reference sections of identified papers to locate additional studies for
inclusion.
Search Strategy and Study Selection
Two investigators (PR and WP) independently screened titles, abstracts, and articles for
eligibility using predefined criteria described below. We required that studies reported findings
in English on anogenital HPV infection. We excluded studies that reported data only on non-
anogenital HPV infections (e.g., oral infections only). We required that studies determined the
HPV status of participants using molecular methods (e.g., DNA hybridization, polymerase
chain reaction [PCR]), as opposed to relying solely on clinical examination or histopathology,
since some individuals with no clinical evidence of HPV infection are positive for HPV DNA
(19) while others with acetowhite anogenital lesions are HPV DNA-negative (20). We required
that studies reported data on heterosexual couples, as HPV transmission dynamics in same-sex
couples may differ.
Data Extraction and Quality Assessment
Two investigators (PR and WP) independently completed standardized data extraction forms
to code study and participant characteristics that could affect HPV concordance. Study
characteristics included study design, specimen collection method, HPV types examined, and
HPV detection methods. Participant characteristics included demographics (age and marital
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status), health (history of HPV-related disease or other STIs and whether males were
circumcised), sexual history (age at first intercourse and number of lifetime sexual partners),
and relationship characteristics (length of time couples had been together, condom use, and
whether couples were monogamous). A third investigator (NB) resolved the few coding
disagreements. For case-control studies, we treated cases and controls as separate study
samples, as “cases” (e.g., women with cervical cancer) may have higher chances of infecting
their partners with HPV than would “controls” (e.g., women with normal Pap smear test
results).
Reviewers extracted data on the status of each partner for infection with any HPV type and
HPV types 6, 11, 16, and 18. We examined these 4 HPV types as they are the primary causes
of HPV-related diseases (e.g., genital warts, cervical cancer, and anal cancer (7–9)) and recently
licensed HPV vaccines protect against 2 or all 4 of these viral types (21–23). Reviewers created
measures of positive concordance, defined as both partners having the HPV outcome of
interest. Thus, both partners being negative did not increase concordance. We usually refer to
positive concordance simply as concordance for the remainder of this report. We examined
any-type concordance (both partners had HPV), same-type concordance (both partners had 1
or more HPV types in common), and type-specific concordance for HPV types 6, 11, 16, and
18.
We required that studies reported HPV infection data for both members of couples in a manner
that allowed us to assess at least 1 of these HPV concordance measures. We included type-
specific concordance only for studies that reported data that did not combine multiple HPV
types (e.g., the HPV DNA probe indicated the presence of either HPV type 16 or 18). During
data extraction, we excluded articles that inconsistently reported concordance data that queries
to the authors did not resolve.
Data Synthesis and Analysis
We pooled data across studies using random-effects meta-analysis to examine any-type
concordance, same-type concordance, and type-specific HPV concordance among couples.
Using methods similar to those from previous studies (24,25), we determined if concordance
levels for HPV types 6, 11, 16, an 18 were higher than chance would predict by calculating
expected concordance levels and using random-effects meta-analysis to calculate odds ratios
(ORs) and 95% confidence intervals (CIs). Analyses also examined sex-dependent same-type
concordance, defined as the proportion of men who had the same HPV types (1 or more types)
as their HPV-positive female partners and the proportion of women who had the same HPV
types (1 or more types) as their HPV-positive male partners. We examined potential correlates
of sex-dependent concordance using random-effects meta-regression, using two-tailed tests
and 0.05 as the critical alpha. Analyses excluded a study that reported data on only 1 couple,
because the absence of study-level variance precluded its inclusion in random-effects meta-
analyses. For random-effects meta-analyses, we report I2 values as an indication of
heterogeneity among studies. We conducted all analyses using Comprehensive Meta-Analysis
Version 2 software (Englewood, NJ).
Results
Of the 2,070 titles and abstracts and 130 articles that we reviewed, 30 articles met inclusion
criteria (Figure 1) (24–53). These articles reported data from 33 study populations that included
HPV concordance data for 2,972 couples (median=45, range=4–499) (Table 1). Studies
provided too few data to report meaningful summary statistics on participant characteristics.
Year of study publication ranged from 1985 to 2008 (median=1994). Study locations included
Europe (52%), Asia (36%), Latin America (15%), and the United States (9%). Most studies
used cohort (76%) and cross-sectional (88%) study designs. Researchers collected specimens
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from a wide range of anatomic sites using various methods. To detect HPV, most studies used
DNA hybridization alone (42%) or in combination with PCR (42%). While most studies (61%)
tested for 5 or more HPV types, the most common were HPV types 16 (100%), 18 (94%), 6
(70%), and 11 (70%).
Both partners in 37.7% of couples were infected with any type of HPV (Table 2). In 25.5% of
couples, both partners were infected with 1 or more of the same HPV types. More couples had
both members infected with HPV type 16 (9.0%) or type 6 (8.6%) than with type 11 (4.6%)
or type 18 (2.2%). Concordance was higher than chance would predict for HPV types 11, 16,
and 18 (all p<0.05), while concordance for HPV type 6 reached borderline statistical
significance (p=0.06) (Table 3). In couples where both members were HPV-positive, 63.2%
were infected with 1 or more of the same HPV types (Table 2).
Same-type concordance for people with HPV-infected partners was lower for men than women
(Table 4, Figures 2 and 3). Among male partners of HPV-positive women, 36.1% (95% CI:
22.7%-52.0%) were infected with 1 or more of the same HPV types. Conversely, among female
partners of HPV-positive men, 55.1% (95% CI: 40.3%-69.1%) were infected with 1 or more
of the same HPV types.
We further refined these sex-dependent concordance estimates by stratifying on whether
studies recruited individuals with HPV or HPV-related disease (e.g., invasive cervical cancer)
and their partners. Men with HPV-positive female partners had 1 or more of the same HPV
types more often in studies that recruited men with HPV-related disease (65.8%, 95% CI:
48.5%-79.7%) compared to studies without this inclusion criterion for men (27.2%, 95% CI:
15.0%-44.2%) (p=0.002; Table 4). We did not find this difference for women. Same-type
concordance was equally high in studies that recruited couples with women having HPV-
related disease (51.9%, 95% CI: 34.3%-69.1%) compared to studies that did not recruit women
with HPV-related disease (63.0%, 95% CI: 39.2%-81.9%) (p=0.463).
We further examined these sex-dependent concordance estimates for potential correlates. For
men, we examined only studies that did not recruit men with HPV-related disease (k=12
studies), since this was shown to strongly affect concordance levels. Because we did not find
this difference for women, we included all studies (k=15 studies). Among men, studies that
used PCR to detect HPV had higher same-type concordance (k=10 studies, 35.0%, 95% CI:
20.5%-52.9%) compared to studies that did not use PCR (k=2 studies, 2.7%, 95% CI:
0.8%-8.9%) (p<0.001), where concordance was defined as the proportion of men positive for
1 or more of the same HPV types as their HPV-infected female partners. None of the other
variables examined (specimen collection site for men, number of HPV types tested for, year
of article publication, study location) were associated with sex-dependent concordance.
Among women, number of HPV types tested for, year of article publication, whether the study
used PCR, and study location were not associated with sex-dependent concordance.
Discussion
Our comprehensive review of data from several thousand heterosexual couples from 4
continents found moderate to high positive concordance, defined as both partners having the
HPV outcome of interest. Concordance was greater than one would expect by chance for HPV
types 11, 16 and 18, and results were suggestive for HPV type 6. While 2 small primary studies
have reported similar results (24,25), our meta-analysis confirms these findings in a
substantially larger and more diverse sample. Of couples in which both members were HPV-
positive, about two thirds (63.2%) were infected with 1 or more of the same HPV types. This
level of concordance is consistent with the high transmissibility of HPV (16).
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Our finding that female coital partners of HPV-positive men were more likely to be infected
with the same types of HPV (1 or more types) compared to male partners of HPV-positive
women makes sense, given that women may be more susceptible to HPV infection and take
longer to clear HPV infections than men (4–6,17,18,54). Exposure to HPV in men often
involves the keratinized epithelium of the penis that may be less susceptible to HPV infection
than the mucosal epithelium of the cervix (54). HPV infections may also persist longer in
women compared to men. Estimates of the median duration of HPV infections among women
have ranged from 4.3–11.1 months for nononcogenic HPV types and from 6.5–14.8 months
for oncogenic HPV types (4,6,17,18). Among men, the median duration of HPV infections is
about 6 months for both oncogenic and nononcogenic HPV types (5), with circumcision
possibly reducing HPV acquisition and speeding clearance (55–57). The gender difference did
not appear in studies where recruitment involved individuals with HPV-related disease.
However, in studies where recruitment did not involve individuals with HPV-related disease,
the difference was apparent and may be partly due to sampling from suboptimal anatomic sites
and difficulty in obtaining adequate specimens, problems that occur more often when testing
men for HPV (58,59).
HPV concordance in heterosexual couples has important clinical and public health
implications. HPV infection and subsequent HPV-related disease pose a substantial burden
worldwide (10). Female partners of men with HPV-related disease should be encouraged to
get screened for HPV-related disease given that they have a high likelihood of concomitant
infection and that most HPV infections in couples are of the same viral types. Screening may
also benefit male partners of HPV-infected women, though an HPV DNA test has not yet been
approved for clinical use in men. Partners of HPV-infected individuals may receive additional
benefits from educational counseling and screening for other STIs if encouraged to see a
healthcare provider (60). However, only 62% of healthcare providers encourage women with
either abnormal Pap smears or positive HPV tests to tell their sexual partners to see a clinician
(61). We are not aware of data regarding referral of female partners of men with HPV-related
disease, but high concordance levels suggest clinicians may be missing many opportunities to
encourage HPV-infected patients to notify their partners and encourage them to seek care. It
is likely that many of these partners are unknowingly infected with HPV and may be at risk
for HPV-related disease.
Uninfected sexual partners may be an important target population for HPV vaccination,
provided they are in the recommended age range for HPV vaccine. The Advisory Committee
on Immunization Practices (ACIP) currently recommends routine vaccination of females aged
11–12 years with catch-up vaccination for females through age 26 (21,22), while providing a
permissive recommendation for HPV vaccination of males aged 9–26 years (23). The benefits
of vaccination to individuals seronegative to HPV types included in the vaccine are clear, and
emerging evidence suggests that HPV vaccine may also help people who previously had and
cleared an infection (62,63), though additional research among such individuals is needed. It
is unlikely that people have been infected with all 4 HPV types in the quadrivalent HPV vaccine
(64), making the vaccine a potentially beneficial prophylaxis for people already exposed to
some HPV types. Women’s higher rates of infection when their partners are HPV-positive lend
further support to the recommendations of the ACIP, which made a stronger recommendation
for HPV vaccination among age-appropriate females than males (21–23). Our findings may
provide HPV vaccine cost-effectiveness analyses with increased precision when estimating the
potential consequences of having a sexual partner who is HPV-positive and how it may differ
for males and females.
Strengths of our meta-analysis include a comprehensive search strategy, careful data extraction
methods, and use of random-effects modeling techniques. The few additional studies identified
after we searched PubMed suggests that we identified most relevant published studies. We
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identified some important sources of variability in study concordance estimates, but because
of poor reporting by primary studies, we were unable to identify additional sources of variation
that we believe are likely to exist but are presently unknown. For this reason, we believe that
these concordance levels should be viewed as tentative estimates that may differ for some
populations.
As the field matures, new concordance studies should use more rigorous research designs. All
but a few studies were cross-sectional, meaning many of the studies were not able to establish
the temporality or direction of HPV transmission between sexual partners. Longitudinal
designs of HPV discordant couples would more effectively address the dynamics of HPV
transmission, clearance, and persistent infection (37). More rigorous research designs will have
the added benefit of allowing researchers to move beyond description to more robust hypothesis
testing. More complex study designs would also allow researchers to better understand first
transmission, re-infection and back-and-forth passage within couples, concordance in couples
in which 1 partner has received HPV vaccine, and concordance after treatment for HPV-related
lesions.
Concordance studies should also characterize their participants in greater detail and study more
meaningful populations. Fewer studies recruited men with HPV-related disease than recruited
women with such disease. Many studies did not report basic information on participant
demographics, health, sexual history, and relationship characteristics. While studies often used
state of the art methods for determining HPV DNA prevalence, some studies also did not report
basic information on study design and methods. Table 5 describes basic participant, couple,
and study characteristics that we recommend future HPV concordance and transmission studies
consider collecting and reporting. The studies in our meta-analysis sampled geographically
diverse populations, including many in developing countries where the majority of cervical
cancer deaths occur (13). However, no studies were conducted in Africa, parts of which have
the highest cervical cancer mortality rates in the world (13).
Our findings can help inform cost-effectiveness analyses, which have helped guide regulatory
and funding policies regarding HPV vaccine. High quality longitudinal studies are needed to
better understand HPV concordance and transmission among heterosexual couples. In future
efforts, researchers also should be more diligent in reporting characteristics of participants,
couples, and their studies. Reporting such detailed information about participants and couples
may help identify high-risk subsets of individuals that warrant focused interventions to prevent
HPV-related disease. Our findings suggest the need for greater attention to sexual partners of
HPV-infected individuals.
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Forest plot of percent of men with the same HPV types (1 or more types) as their HPV-positive
female partners. Analyses included all men, regardless of HPV status, whose female partners
were HPV-positive and for whom studies reported appropriate concordance data. Results
stratified by whether the study recruited couples that included men with HPV-related disease.
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Forest plot of percent of women with the same HPV types (1 or more types) as their HPV-
positive male partners. Analyses included all women, regardless of HPV status, whose male
partners were HPV-positive and for whom studies reported appropriate concordance data.
Results stratified by whether the study recruited couples that included women with HPV-
related disease.
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Table 5
Characteristics that future HPV concordance and transmission studies should collect and report.
Study Characteristics
 Years of data collection
 Study location
 Study design (e.g., longitudinal)
 Sampling and recruitment methods
 Response rate
 Specimen collection sites and methods
 HPV detection methods
 All HPV types tested for
Participant Characteristics
 Age
 Race / ethnicity
 Socioeconomic status (e.g., education)
 Number of lifetime sexual partners
 Age at first sexual intercourse
 Sexual behavior with same-sex partners
 History of sexually transmitted infections
 Circumcision status for males
Couple Characteristics
 Duration of relationship
 Marital status
 Condom use
 Whether couple is monogamous
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